Yi Duan

Dr. Yi Duan


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2019 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
Bei GaoBei Gao
Bei Gao
LSLang Sonja
Lang Sonja
YDYi Duan
Yi Duan
YWYanhan Wang
Yanhan Wang
DSDebbie L. Shawcross
Debbie L. Shawcross
BSBernd Schnabl
Bernd Schnabl

14 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
NCNoemí Cabré
Noemí Cabré
YDYi Duan
Yi Duan
CLCristina Llorente
Cristina Llorente
MCMary Conrad
Mary Conrad
PSPatrick Stern
Patrick Stern
BSBernd Schnabl
Bernd Schnabl
Alcohol-related liver disease is associated with intestinal dysbiosis. Functional changes in the microbiota affect bile acid metabolism and result in elevated serum bile acids in patients with alcohol-related liver disease. The aim of this study was to identify the potential role of the bile acid sequestrant colesevelam in a humanized mouse model of ethanol-induced liver disease. We colonized germ-free (GF) C57BL/6 mice with feces from patients with alcoholic hepatitis and subjected humanized mice to the chronic–binge ethanol feeding model. Ethanol-fed gnotobiotic mice treated with colesevelam showed reduced hepatic levels of triglycerides and cholesterol, but liver injury and inflammation were not decreased as compared with non-treated mice. Colesevelam reduced hepatic cytochrome P450, family 7, subfamily a, polypeptide 1 (Cyp7a1) protein expression, although serum bile acids were not lowered. In conclusion, our findings indicate that colesevelam treatment mitigates ethanol-induced liver steatosis in mice.